Serum response factor is alternatively spliced in human colon cancer

Patten, Lane C.; Belaguli, Narasimhaswamy S.; Baek, Moo Jun; Fagan, Shawn P.; Awad, Samir S.; Berger, David H.

doi:10.1016/j.jss.2004.02.031

Cited by 22 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal splicing of several genes has been observed in tumors of colorectal origin, including CD44 [4,5], MUC2 [6], SRF [7], NCAM [8], MLH , MSH [9] and members of the Wnt pathway [10]. Some of these alternately spliced gene products may have therapeutic utility as markers of the progression of the disease or as drug targets; however there are insufficient data supporting their relevance in larger clinical populations.…”

Section: Introductionmentioning

confidence: 99%

Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array

Gardina¹,

Clark²,

Shimada³

et al. 2006

BMC Genomics

315

322

View full text Add to dashboard Cite

Background: Alternative splicing is a mechanism for increasing protein diversity by excluding or including exons during post-transcriptional processing. Alternatively spliced proteins are particularly relevant in oncology since they may contribute to the etiology of cancer, provide selective drug targets, or serve as a marker set for cancer diagnosis. While conventional identification of splice variants generally targets individual genes, we present here a new exon-centric array (GeneChip Human Exon 1.0 ST) that allows genome-wide identification of differential splice variation, and concurrently provides a flexible and inclusive analysis of gene expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array

Gardina¹,

Clark²,

Shimada³

et al. 2006

BMC Genomics

315

322

View full text Add to dashboard Cite

show abstract

“…Previously, Patten et al have demonstrated that the SRFΔ5 isoform is overexpressed in a human colon cancer cell line derived from a poorly differentiated tumor (19). These investigators have also suggested that SRFΔ5 contributes to epithelial tumorigenesis through the inhibition of apoptosis.…”

Section: Discussionmentioning

confidence: 98%

The expression and role of serum response factor in papillary carcinoma of the thyroid

Moon¹

2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. Serum response factor (SRF) is a transcription factor of the MADS box family. SRF is involved in various cellular processes such as expression of immediate early and tissuespecific genes, cell proliferation, differentiation and apoptosis. The expression of SRF in papillary thyroid carcinoma (PTC) and its role have not been investigated, forming the basis for this study. Surgical specimens of 63 conventional PTCs along with 30 follicular adenoma, 30 adenomatous hyperplasia and 9 anaplastic carcinoma specimens were obtained from the surgical archives. The expression of SRF was determined by the use of immunohistochemical staining. We also investigated the expression level of SRF and an SRF target gene, c-fos in fresh PTC tissues and thyroid cancer cell lines (NPA, FRO and ARO) by Western blot analyses. In addition, we examined the role of SRF in PTC by overexpresion of SRF in the NPA cell line. SRF was mainly expressed in cancer cells, showing a strong nuclear and/or cytoplasmic staining in PTC. SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). The expression level of SRF was significantly up-regulated in PTC (combined staining score of 5.21±0.43) and anaplastic carcinoma (5.67±1.45) compared to that of follicular adenoma (2.30±0.44) (P<0.001), or adenomatous goiter (1.13±0.28) (P<0.001). Western blot analyses showed an increased expression of the spliced form of SRF protein and c-Fos protein in PTC as compared to non-tumor thyroid tissues. SRF expression correlated with the tumor size of the PTCs (P<0.05). Overexpression of SRF in papillary carcinoma cells enhanced cell motility and invasiveness. Our results indicate that the altered expression of SRF in papillary carcinoma cells may play an important role in PTC carcinogenesis and progression.

show abstract

“…48 In addition, a truncated SRF isoform, SRF∆5 appears to be abnormally overexpressed in colon cancer. 20 Over-expression of this isoform increased cell survival, suggesting that this truncated protein may contribute to colon tumorigenesis. 20 However, in the truncated SRF study, it was not made clear whether the truncated protein alone induced cell growth or whether this truncated protein simply attenuated the effect of SRF.…”

Section: Cancermentioning

confidence: 99%

“…20 Over-expression of this isoform increased cell survival, suggesting that this truncated protein may contribute to colon tumorigenesis. 20 However, in the truncated SRF study, it was not made clear whether the truncated protein alone induced cell growth or whether this truncated protein simply attenuated the effect of SRF. The downregulated SRF that induced gastric cancer 48 suggested the latter may be the case in colon cancer.…”

Section: Cancermentioning

confidence: 99%

See 1 more Smart Citation

Multi-phenotypic Role of Serum Response Factor in the Gastrointestinal System

2016

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Serum response factor (SRF) is a master transcription factor of the actin cytoskeleton that binds to highly conserved CArG boxes located within the majority of smooth muscle cell (SMC)-restricted promoters/enhancers. Although most studies of SRF focus on skeletal muscle, cardiac muscle, and vascular SMCs, SRF research has recently expanded into the gastrointestinal (GI) system. Genome scale analyses of GI SMC transcriptome and CArG boxes (CArGome) have identified new SRF target genes. In addition to circular and longitudinal smooth muscle layers, SRF is also expressed in GI mucosa and cancers. In the GI tract, SRF is the central regulator of genes involved in apoptosis, dedifferentiation, proliferation, and migration of cells. Since SRF is the cell phenotypic modulator, it may play an essential role in the development of myopathy, hypertrophy, ulcers, gastric and colon cancers within the GI tract. Given the multifunctional role displayed by SRF in the digestive system, SRF has received more attention emerging as a potential therapeutic target. This review summarizes the findings in SRF research pertaining to the GI tract and provides valuable insight into future directions.

show abstract

Serum response factor is alternatively spliced in human colon cancer

Cited by 22 publications

References 31 publications

Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array

Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array

The expression and role of serum response factor in papillary carcinoma of the thyroid

Multi-phenotypic Role of Serum Response Factor in the Gastrointestinal System

Contact Info

Product

Resources

About